Double Strike Against Neuroblastoma: Israel and the USA Join Forces

In early March 2025, the Israeli biotechnology company BioMed and a group of American researchers from the National Cancer Institute (NCI) announced the launch of a joint project to develop a vaccine against neuroblastoma — a rare but extremely aggressive cancer of the nervous system that most often affects children under five years old. The project combines advanced Israeli technologies in immunotherapy with American expertise in clinical research.

The first experiments conducted on animal models showed impressive results: tumors decreased by 40% in the test mice after the prototype vaccine was administered. This discovery was made possible by the use of an innovative approach that stimulates the immune system to recognize and destroy cancer cells.

According to Dr. Rafi Levi, head of the BioMed research team, the goal is to create an effective treatment that can replace existing methods, such as chemotherapy, which often causes severe side effects in young patients. A pilot study in humans is scheduled for late 2025 in Israel, highlighting the ambitious timeline of the project.

Mechanism of Action of the Vaccine

The new vaccine works by activating T-cells — key elements of the immune system that can attack tumor cells. It is based on a combination of synthetic peptides specific to neuroblastoma and adjuvants that enhance the immune response. Scientists at BioMed have developed a unique delivery platform that allows for precise targeting of the vaccine to the tumor, minimizing impact on healthy tissues. American partners, in turn, provided data on genetic mutations characteristic of this type of cancer, which helped increase the specificity of the drug.

Unlike traditional vaccines against infections, this development does not prevent disease but treats existing tumors, making it therapeutic. In the preclinical trial phase, the vaccine demonstrated not only a reduction in tumor size but also prevention of metastasis in 60% of cases.

Researchers note that the technology can be adapted for other types of pediatric cancers, opening up prospects for broader application. The teams are currently working on optimizing the vaccine composition and preparing for the transition to the clinical phase.

Significance for Children and Medicine

Neuroblastoma is diagnosed in thousands of children worldwide each year, and in half of the cases, the disease is detected at the metastatic stage, when survival chances are less than 50%. The collaboration between Israel and the USA in developing the vaccine offers hope for a breakthrough in treating this severe disease. The success of the project could radically change therapy standards, reducing reliance on aggressive methods such as high-dose chemotherapy and bone marrow transplantation.

After the completion of pilot trials in Israel at the end of 2025, an expansion of research in the USA is planned, where the NCI will allocate additional resources to accelerate the process. Experts predict that if successful, the vaccine will be available to patients by 2028, saving thousands of lives. This collaboration also strengthens Israel's position as a leader in oncology innovations and underscores the importance of international partnerships in the fight against cancer. Parents of children with neuroblastoma and charitable foundations have already expressed support for the project, awaiting its results with great optimism.